Loading...
Loading...
In a report published Friday, Jefferies & Company reiterated its Hold rating on Metabolix
MBLX, but slightly lowered its price target from $2.20 to $1.50.
Jefferies noted, “We expect the technology value of Metabolix's PHA IP to continue to be masked by uncertainty as to what economics it may be able to capture on manufacturing partnerships, as well as whether a step up in its cash burn will be required to move biochemical partnerships to commercialization. We reiterate our Hold rating.”
Metabolix closed on Thursday at $1.32.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsBiotechnologyHealth CareJefferies & Company
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in